ArticleWorld journal of surgical oncology2026
A pathological morphology parameter-based prognostic nomogram for high-risk prostate cancer patients treated with neoadjuvant therapy followed by radical prostatectomy: a retrospective study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe prognostic value of these pathological morphology alterations induced by neoadjuvant therapy in high-risk prostate cancer (PCa) patients is still unclear. Hence, this study retrospectively reviewed the data of 124 patients with high-risk PCa who underwent neoadjuvant therapy followed by radical prostatectomy (RP), and aimed to explore the prognostic value of pathological morphology alterations.
methodsData from 124 patients with high-risk PCa who underwent neoadjuvant therapy followed by RP were retrospectively reviewed. Pathological morphology alterations observed in RP specimens were independently recorded by two uropathologists, and the primary endpoint was biochemical progression-free survival (bPFS). Cox regression analyses were performed to explore independent predictors of bPFS, and a nomogram was developed. The C-index, calibration curves and decision curve analysis (DCA) were used to evaluate the performance of the nomogram.
resultsAmong 124 patients, 66 patients (53.2%) were treated with neoadjuvant hormonal therapy (NHT), and 58 patients (46.8%) were treated with neoadjuvant chemohormonal therapy (NCHT). Moreover, 11 patients (8.9%) had a complete reduction in glandular density and diameter, and intraductal carcinoma of the prostate (IDC-P) was observed in 8 patients (6.5%). Cox regression revealed that NHT, pelvic lymph node (LN) metastasis, positive surgical margins, negative reduction in glandular density and diameter, and IDC-P were associated with worse bPFS (all P < 0.05), and those factors were subsequently selected to develop a nomogram. The C-index was 0.813 (95% CI: 0.626-0.863), and time-dependent C-index were 0.902 (6 months), 0.882 (12 months), and 0.951 (24 months). The calibration curves showed a high consistency between the predicted and observed bPFS probabilities, and DCA confirmed the nomogram's clinical utility across a range of threshold probabilities.
conclusionsPelvic LN metastasis, positive surgical margins and IDC-P were independent prognostic factors for high-risk PCa, and NCHT might significantly improve bPFS compared with the NHT. In addition, the degree of reduction in glandular density and diameter was also associated with bPFS, and the nomogram based on pathological morphology parameters-intended for postoperative risk stratification-might be helpful in clinical decision-making.
trial registrationRetrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.